Novartis AG (NYSE:NVS) previous close was $87.98 while the outstanding shares total 2.25B. The firm has a beta of 0.57, a 12-month trailing P/E ratio of 25.14, and a growth ratio of 3.22. NVS’s shares traded lower over the last trading session, losing -0.65% on 05/11/21. The shares fell to a low of $87.072 before closing at $87.41. Intraday shares traded counted 1.74 million, which was 8.1% higher than its 30-day average trading volume of 1.89M. The stock’s Relative Strength Index (RSI) is 52.04, with weekly volatility at 0.73% and ATR at 0.90. The NVS stock’s 52-week price range has touched low of $77.04 and a $98.52 high.
Investors have identified the Drug Manufacturers – General company Novartis AG as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $212.40 billion, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Novartis AG (NVS) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. For NVS, the company has in raw cash 3.8 billion on their books with 10.16 billion currently as liabilities. How the trend is over time is what investors should be concerned about. The company has a healthy balance sheet as their debt profile has been on an incline. In terms of their assets, the company currently has 22.2 billion total, with 30.16 billion as their total liabilities.
Having a look at the company’s valuation, the company is expected to record 6.75 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on NVS sounds very interesting.
Is the stock of NVS attractive?
In related news, Former 10% Owner, Novartis Bioventures Ltd bought 125,000 shares of the company’s stock in a transaction that recorded on Jun 30. The purchase was performed at an average price of 17.00, for a total value of 2,125,000. In the last 6 months, insiders have changed their ownership in shares of company stock by 9.30%.
15 out of 28 analysts covering the stock have rated it a Buy, while 9 have maintained a Hold recommendation on Novartis AG. 2 analysts has assigned a Sell rating on the NVS stock. The 12-month mean consensus price target for the company’s shares has been set at $104.67.